SWI/SNF component ARID1A restrains pancreatic neoplasia formation

Sam C. Wang, Ibrahim Nassour, Shu Xiao, Shuyuan Zhang, Xin Luo, Jeon Lee, Lin Li, Xuxu Sun, Liem H. Nguyen, Jen Chieh Chuang, Lan Peng, Scott Daigle, Jeanne Shen, Hao Zhu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: ARID1A is commonly mutated in pancreatic ductal adenocarcinoma (PDAC), but the functional effects of ARID1A mutations in the pancreas are unclear. Understanding the molecular mechanisms that drive PDAC formation may lead to novel therapies. Design: Concurrent conditional Arid1a deletion and Kras activation mutations were modelled in mice. Small-interfering RNA (siRNA) and CRISPR/Cas9 were used to abrogate ARID1A in human pancreatic ductal epithelial cells. Results: We found that pancreas-specific Arid1a loss in mice was sufficient to induce inflammation, pancreatic intraepithelial neoplasia (PanIN) and mucinous cysts. Concurrent Kras activation accelerated the development of cysts that resembled intraductal papillary mucinous neoplasm. Lineage-specific Arid1a deletion confirmed compartment-specific tumour-suppressive effects. Duct-specific Arid1a loss promoted dilated ducts with occasional cyst and PDAC formation. Heterozygous acinar-specific Arid1a loss resulted in accelerated PanIN and PDAC formation with worse survival. RNA-seq showed that Arid1a loss induced gene networks associated with Myc activity and protein translation. ARID1A knockdown in human pancreatic ductal epithelial cells induced increased MYC expression and protein synthesis that was abrogated with MYC knockdown. ChIP-seq against H3K27ac demonstrated an increase in activated enhancers/promoters. Conclusions: Arid1a suppresses pancreatic neoplasia in a compartment-specific manner. In duct cells, this process appears to be associated with MYC-facilitated protein synthesis.

Original languageEnglish (US)
JournalGut
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Adenocarcinoma
Neoplasms
Cysts
Pancreas
Clustered Regularly Interspaced Short Palindromic Repeats
Epithelial Cells
Pancreatic Cyst
Mutation
Gene Regulatory Networks
Protein Biosynthesis
Small Interfering RNA
Proteins
RNA
Inflammation
Survival
Therapeutics

Keywords

  • cancer genetics
  • pancreatic cancer
  • pancreatic tumours

ASJC Scopus subject areas

  • Gastroenterology

Cite this

SWI/SNF component ARID1A restrains pancreatic neoplasia formation. / Wang, Sam C.; Nassour, Ibrahim; Xiao, Shu; Zhang, Shuyuan; Luo, Xin; Lee, Jeon; Li, Lin; Sun, Xuxu; Nguyen, Liem H.; Chuang, Jen Chieh; Peng, Lan; Daigle, Scott; Shen, Jeanne; Zhu, Hao.

In: Gut, 01.01.2018.

Research output: Contribution to journalArticle

Wang, SC, Nassour, I, Xiao, S, Zhang, S, Luo, X, Lee, J, Li, L, Sun, X, Nguyen, LH, Chuang, JC, Peng, L, Daigle, S, Shen, J & Zhu, H 2018, 'SWI/SNF component ARID1A restrains pancreatic neoplasia formation', Gut. https://doi.org/10.1136/gutjnl-2017-315490
Wang, Sam C. ; Nassour, Ibrahim ; Xiao, Shu ; Zhang, Shuyuan ; Luo, Xin ; Lee, Jeon ; Li, Lin ; Sun, Xuxu ; Nguyen, Liem H. ; Chuang, Jen Chieh ; Peng, Lan ; Daigle, Scott ; Shen, Jeanne ; Zhu, Hao. / SWI/SNF component ARID1A restrains pancreatic neoplasia formation. In: Gut. 2018.
@article{298c46f4795f4ddf805b244549024488,
title = "SWI/SNF component ARID1A restrains pancreatic neoplasia formation",
abstract = "Objective: ARID1A is commonly mutated in pancreatic ductal adenocarcinoma (PDAC), but the functional effects of ARID1A mutations in the pancreas are unclear. Understanding the molecular mechanisms that drive PDAC formation may lead to novel therapies. Design: Concurrent conditional Arid1a deletion and Kras activation mutations were modelled in mice. Small-interfering RNA (siRNA) and CRISPR/Cas9 were used to abrogate ARID1A in human pancreatic ductal epithelial cells. Results: We found that pancreas-specific Arid1a loss in mice was sufficient to induce inflammation, pancreatic intraepithelial neoplasia (PanIN) and mucinous cysts. Concurrent Kras activation accelerated the development of cysts that resembled intraductal papillary mucinous neoplasm. Lineage-specific Arid1a deletion confirmed compartment-specific tumour-suppressive effects. Duct-specific Arid1a loss promoted dilated ducts with occasional cyst and PDAC formation. Heterozygous acinar-specific Arid1a loss resulted in accelerated PanIN and PDAC formation with worse survival. RNA-seq showed that Arid1a loss induced gene networks associated with Myc activity and protein translation. ARID1A knockdown in human pancreatic ductal epithelial cells induced increased MYC expression and protein synthesis that was abrogated with MYC knockdown. ChIP-seq against H3K27ac demonstrated an increase in activated enhancers/promoters. Conclusions: Arid1a suppresses pancreatic neoplasia in a compartment-specific manner. In duct cells, this process appears to be associated with MYC-facilitated protein synthesis.",
keywords = "cancer genetics, pancreatic cancer, pancreatic tumours",
author = "Wang, {Sam C.} and Ibrahim Nassour and Shu Xiao and Shuyuan Zhang and Xin Luo and Jeon Lee and Lin Li and Xuxu Sun and Nguyen, {Liem H.} and Chuang, {Jen Chieh} and Lan Peng and Scott Daigle and Jeanne Shen and Hao Zhu",
year = "2018",
month = "1",
day = "1",
doi = "10.1136/gutjnl-2017-315490",
language = "English (US)",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - SWI/SNF component ARID1A restrains pancreatic neoplasia formation

AU - Wang, Sam C.

AU - Nassour, Ibrahim

AU - Xiao, Shu

AU - Zhang, Shuyuan

AU - Luo, Xin

AU - Lee, Jeon

AU - Li, Lin

AU - Sun, Xuxu

AU - Nguyen, Liem H.

AU - Chuang, Jen Chieh

AU - Peng, Lan

AU - Daigle, Scott

AU - Shen, Jeanne

AU - Zhu, Hao

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: ARID1A is commonly mutated in pancreatic ductal adenocarcinoma (PDAC), but the functional effects of ARID1A mutations in the pancreas are unclear. Understanding the molecular mechanisms that drive PDAC formation may lead to novel therapies. Design: Concurrent conditional Arid1a deletion and Kras activation mutations were modelled in mice. Small-interfering RNA (siRNA) and CRISPR/Cas9 were used to abrogate ARID1A in human pancreatic ductal epithelial cells. Results: We found that pancreas-specific Arid1a loss in mice was sufficient to induce inflammation, pancreatic intraepithelial neoplasia (PanIN) and mucinous cysts. Concurrent Kras activation accelerated the development of cysts that resembled intraductal papillary mucinous neoplasm. Lineage-specific Arid1a deletion confirmed compartment-specific tumour-suppressive effects. Duct-specific Arid1a loss promoted dilated ducts with occasional cyst and PDAC formation. Heterozygous acinar-specific Arid1a loss resulted in accelerated PanIN and PDAC formation with worse survival. RNA-seq showed that Arid1a loss induced gene networks associated with Myc activity and protein translation. ARID1A knockdown in human pancreatic ductal epithelial cells induced increased MYC expression and protein synthesis that was abrogated with MYC knockdown. ChIP-seq against H3K27ac demonstrated an increase in activated enhancers/promoters. Conclusions: Arid1a suppresses pancreatic neoplasia in a compartment-specific manner. In duct cells, this process appears to be associated with MYC-facilitated protein synthesis.

AB - Objective: ARID1A is commonly mutated in pancreatic ductal adenocarcinoma (PDAC), but the functional effects of ARID1A mutations in the pancreas are unclear. Understanding the molecular mechanisms that drive PDAC formation may lead to novel therapies. Design: Concurrent conditional Arid1a deletion and Kras activation mutations were modelled in mice. Small-interfering RNA (siRNA) and CRISPR/Cas9 were used to abrogate ARID1A in human pancreatic ductal epithelial cells. Results: We found that pancreas-specific Arid1a loss in mice was sufficient to induce inflammation, pancreatic intraepithelial neoplasia (PanIN) and mucinous cysts. Concurrent Kras activation accelerated the development of cysts that resembled intraductal papillary mucinous neoplasm. Lineage-specific Arid1a deletion confirmed compartment-specific tumour-suppressive effects. Duct-specific Arid1a loss promoted dilated ducts with occasional cyst and PDAC formation. Heterozygous acinar-specific Arid1a loss resulted in accelerated PanIN and PDAC formation with worse survival. RNA-seq showed that Arid1a loss induced gene networks associated with Myc activity and protein translation. ARID1A knockdown in human pancreatic ductal epithelial cells induced increased MYC expression and protein synthesis that was abrogated with MYC knockdown. ChIP-seq against H3K27ac demonstrated an increase in activated enhancers/promoters. Conclusions: Arid1a suppresses pancreatic neoplasia in a compartment-specific manner. In duct cells, this process appears to be associated with MYC-facilitated protein synthesis.

KW - cancer genetics

KW - pancreatic cancer

KW - pancreatic tumours

UR - http://www.scopus.com/inward/record.url?scp=85054790318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054790318&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2017-315490

DO - 10.1136/gutjnl-2017-315490

M3 - Article

C2 - 30315093

AN - SCOPUS:85054790318

JO - Gut

JF - Gut

SN - 0017-5749

ER -